These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 25243962

  • 1. [Clinical effect of combination therapy with Fufang Biejia Ruangan tablet and entecavir in patients with hepatitis B virus-related cirrhosis].
    Wu G, He H, Li H, Chen W.
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):604-8. PubMed ID: 25243962
    [Abstract] [Full Text] [Related]

  • 2. [Entecavir combined with Fufang Biejia Ruangan tablet in treatment of chronic hepatitis B patients with liver fibrosis: 96-week efficacy analyses].
    Yang NH, Yuan GS, Zhou YC, Liu JW, Huang HP, Hu CG, Xiong L, Li Y, Zhou FY, Yang SL, Zhou YP.
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jun; 36(6):775-9. PubMed ID: 27320877
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy and safety of Fufang Biejia Ruangan tablet in patients with chronic hepatitis B complicated with hepatic fibrosis].
    Chen JM, Yang YP, Chen DY, Han J, Jin XY, Huang ZX, Xu CB, Shen YM.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Dec; 21(4):358-60. PubMed ID: 18322602
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis.
    Meng X, Pan Z, Zhao J, Feng Q.
    Medicine (Baltimore); 2022 Nov 18; 101(46):e31664. PubMed ID: 36401442
    [Abstract] [Full Text] [Related]

  • 5. [Study on rational daily administration frequency of Fufang Biejia Ruangan tablet based on integrated serum pharmacologic and pharmacokinetic model].
    Bai JX, Dai L, Chen HG, Xu H, Yin RL, Han J, Yuan HL.
    Zhongguo Zhong Yao Za Zhi; 2013 Jul 18; 38(14):2394-8. PubMed ID: 24199579
    [Abstract] [Full Text] [Related]

  • 6. [Therapeutic efficacy and quality of life investigation of traditional Chinese medicine-based therapy of chronic hepatitis B-related liver fibrosis].
    An J, Ni W, Qiao J.
    Zhonghua Gan Zang Bing Za Zhi; 2014 Jan 18; 22(1):30-2. PubMed ID: 24721240
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of influences of Biejiajian Pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: Protocol of systematic review and meta-analysis.
    Zhang T, Yang Y, Wang B, Zheng X, Wang L, Feng X, Li G, Shi J, Cao N.
    Medicine (Baltimore); 2019 Dec 18; 98(51):e18458. PubMed ID: 31861022
    [Abstract] [Full Text] [Related]

  • 8. Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies.
    Huang C, Shen D, Sun S, Huang Y, Xin Y, Luo H, Chen Y, Zhou Z, Liu F, Chen X.
    Medicine (Baltimore); 2019 Apr 18; 98(17):e15297. PubMed ID: 31027094
    [Abstract] [Full Text] [Related]

  • 9. [Intervention of chronic hepatitis B liver fibrosis patients in different stages by syndrome typing and different activating blood removing stasis methods: a clinical study].
    Liu SY, Zhang YQ, Liu YL, Guo P, Zhou CM.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Nov 18; 33(11):1457-61. PubMed ID: 24483103
    [Abstract] [Full Text] [Related]

  • 10. Compound Biejia-Ruangan tablet as an adjunctive therapy to entecavir for chronic hepatitis B complicated with hepatic fibrosis: A systematic review and meta-analysis of randomized controlled trials.
    Xu YH, Xue C.
    Medicine (Baltimore); 2022 Aug 12; 101(32):e30020. PubMed ID: 35960113
    [Abstract] [Full Text] [Related]

  • 11. [Supplemental Fuzhenghuayu capsule therapy for improving liver fibrosis markers in patients with chronic hepatitis B following unsatisfactory outcome of nucleos(t)ide analogue monotherapy].
    Tian YL, Zhu XY, Yin WW, Zang ZD, Wang L, Fu XL.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul 12; 21(7):514-8. PubMed ID: 24074710
    [Abstract] [Full Text] [Related]

  • 12. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial.
    Qu J, Yu Z, Li Q, Chen Y, Xiang D, Tan L, Lei C, Bai W, Li H, Shang Q, Chen L, Hu X, Lu W, Li Z, Chen D, Wang X, Zhang C, Xiao G, Qi X, Chen J, Zhou L, Chen G, Li Y, Zeng Z, Rong G, Dong Z, Chen Y, Lou M, Wang C, Lu Y, Zhang C, Yang Y.
    Trials; 2014 Nov 10; 15():438. PubMed ID: 25381721
    [Abstract] [Full Text] [Related]

  • 13. [The effect of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis: a randomized, double blind, placebo controlled clinical trial].
    Yin SS, Wang BE, Wang TL, Jia JD, Qian LX.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug 10; 12(8):467-70. PubMed ID: 15329205
    [Abstract] [Full Text] [Related]

  • 14. Clinical and virological response to entecavir in HBV-related chronic hepatitis or cirrhosis: data from the clinical practice in a single-centre cohort.
    Marengo A, Bitetto D, D'Avolio A, Ciancio A, Fabris C, Marietti M, Toniutto P, Di Perri G, Rizzetto M, Marzano A.
    Antivir Ther; 2013 Aug 10; 18(1):87-94. PubMed ID: 22872649
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O.
    Clin Gastroenterol Hepatol; 2013 Jan 10; 11(1):88-94. PubMed ID: 23063679
    [Abstract] [Full Text] [Related]

  • 16. [Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection].
    Miao L, Yang WN, Dong XQ, Zhang ZQ, Xie SB, Zhang DZ, Zhang XQ, Cheng J, Zhang G, Zhao WF, Xie Q, Liu YX, Ma AL, Li J, Shang J, Bai L, Cao LH, Zou ZQ, Li JB, Lyu FD, Liu H, Wang ZJ, Zhang MX, Chen LM, Liang WF, Gao H, Zhuang H, Zhao H, Wang GQ.
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jul 20; 27(7):521-526. PubMed ID: 31357778
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis.
    Hyun JJ, Seo YS, Yoon E, Kim TH, Kim DJ, Kang HS, Jung ES, Kim JH, An H, Kim JH, Yim HJ, Yeon JE, Lee HS, Byun KS, Um SH, Kim CD, Ryu HS.
    Liver Int; 2012 Apr 20; 32(4):656-64. PubMed ID: 22099071
    [Abstract] [Full Text] [Related]

  • 18. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP.
    Clin Ther; 2010 Apr 20; 32(4):649-58. PubMed ID: 20435234
    [Abstract] [Full Text] [Related]

  • 19. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.
    Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF.
    Hepatology; 2013 Dec 20; 58(6):1888-96. PubMed ID: 23744454
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the efficacy of Biejia decoction pill combined with entecavir in the treatment of hepatitis B liver fibrosis/cirrhosis by VCTE.
    Wan L, Hu C, Wang F, Xu K, Li F, He B, Wu Z, Luo L, Wen Z.
    Sci Rep; 2023 Nov 10; 13(1):19616. PubMed ID: 37949927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.